Vical Incorporated (NASDAQ:VICL)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.84. Vical shares last traded at $0.81, with a volume of 725,083 shares changing hands.
A number of brokerages have recently commented on VICL. Zacks Investment Research raised shares of Vical from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Friday, July 19th. ValuEngine raised shares of Vical from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
The company has a market cap of $18.38 million, a P/E ratio of -1.00 and a beta of 0.31. The company has a 50-day simple moving average of $0.78.
Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in Vical in the 1st quarter valued at about $146,000. Acadian Asset Management LLC lifted its holdings in Vical by 23.0% in the 1st quarter. Acadian Asset Management LLC now owns 219,221 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 41,036 shares in the last quarter. Finally, Fosun International Ltd purchased a new position in Vical in the 2nd quarter valued at about $265,000. Institutional investors own 33.73% of the company’s stock.
Vical Company Profile (NASDAQ:VICL)
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Read More: What are the benefits of momentum investing?
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.